[Form 4] TENAX THERAPEUTICS, INC. Insider Trading Activity
Tenax Therapeutics director Michael H. Davidson reported a new equity award and his current holdings in company securities.
Rhea-AI Filing Summary
Tenax Therapeutics director Michael H. Davidson reported a new equity award and his current holdings in company securities. On 01/09/2026, he was granted a stock option to buy 30,000 shares of Tenax Therapeutics common stock at an exercise price of $13.3 per share, expiring on 01/09/2036. Following this grant, he holds 2,881 shares of common stock directly.
He also reports several existing derivative positions, including stock options covering 100,000 shares exercisable from 12/10/2025 to 12/10/2034, and options for 80,000 shares exercisable from 07/01/2026 to 07/01/2035, plus smaller option positions. In addition, he holds a pre-funded warrant for 47,500 shares with a $0.01 exercise price and no expiration date, and a warrant for 25,000 shares with a $4.5 exercise price that can terminate based on Phase 3 LEVEL Study topline data timing or on August 8, 2029.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 30,000 | $0.00 | $0.00 |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Pre-Funded Warrant | -- | -- | -- |
| holding | Warrant | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (2)
- F1. The pre-funded warrant has no expiration date.
- F2. The warrant will expire on the earlier of (i) thirty (30) trading days following the date of the Issuer's initial public announcement of topline data from its Phase 3 LEVEL Study (LEVosimendan to Improve Exercise Limitation in PH-HFpEF Patients) ( NCT05983250 ) (the "Topline Data Announcement"); (ii) proportionally upon the exercise of the Reporting Person's pre-funded warrant issued on August 8, 2024, if such exercise is prior to the Topline Data Announcement; and (iii) August 8, 2029.
AI-generated analysis. How Rhea-AI works. Not financial advice.
